Company intelligence / Profile preview

ReNeuron

Bridgend, Wales, United Kingdomreneuron.com ↗

Ownership: Private
Employees: ~34
Development stage: Other

Overview

ReNeuron has developed proprietary stem cell and exosome platforms for off-the-shelf therapies targeting major unmet needs. The company’s lead programs have reached clinical development in areas such as stroke disability and retinitis pigmentosa. Recent focus has shifted toward engineered exosomes for targeted delivery applications. The company recently exited administration and continues operations as a going concern.

Therapeutic areas: OphthalmologyOncologyEndocrinologyNeurology
Modalities: Exosome-based therapyStem cell therapy
Industry: Biotech

Drug pipeline

5 assets

CTX0E03 DP

4 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships disclosed in current sources; historically engaged with academic collaborators.

Beyond the preview

Go deeper on ReNeuron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReNeuron.

Explore the full profile